Agenus Is A Buy Long Term, Despite Short Interest [Seeking Alpha]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Seeking Alpha
Agenus Is A Buy Long Term, Despite Short Interest Summary Agenus is trading well lower from January levels. Short interest is high. Gilead deal and pipeline keep it in my "strong buy" column. Agenus ( AGEN I believe the likely explanation for the slump is a lack of news, combined with the long timelines for getting cancer therapies from conception to commercial sales. However, there have also been attempts to knock clinical stage companies into bankruptcy by short raiders, and Agenus may be one of their targets. I will go into this in more detail below. My main thesis is that Agenus will make fortunes for its investors as its pipeline matures. Despite its small size (market capitalization $357 million), it is a leader in immune therapies. It could even be considered to be a commercial stage company, since it licensed an ingredient to GlaxoSmithKline ( GSK Shingrix In addition, I think the short sellers will fail, since Agenus should be able to get cash support from partners and invest
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Global Vaccine Adjuvants Market Size To Worth USD 1.51 Billion By 2033 | CAGR of 3.9% [Yahoo! Finance]Yahoo! Finance
- SaponiQx and InvivoGen Announce Agreement for SaponiQx to Supply Cultured Plant Cell QS-21 Adjuvant [Yahoo! Finance]Yahoo! Finance
- Agenus Inc. (NASDAQ: AGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Down 75%. Is Agenus Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- Agenus announces reverse stock split of common stock [Seeking Alpha]Seeking Alpha
AGEN
Earnings
- 3/14/24 - Miss
AGEN
Analyst Actions
- 3/18/24 - HC Wainwright
AGEN
Sec Filings
- 4/8/24 - Form 4
- 4/5/24 - Form 8-K
- 4/1/24 - Form 4
- AGEN's page on the SEC website